There is no established medical framework that divides perimenopause into seven discrete stages. The idea of “7 stages of perimenopause” circulates widely on health blogs and social media, but it does not come from any clinical guideline or peer-reviewed staging system. What reproductive medicine actually uses is a broader map called STRAW+10, which charts the entire arc of reproductive aging from early fertility through late postmenopause. Within that map, perimenopause occupies just two formal stages, plus a transitional lead-in that most people experience without realizing anything has changed. Understanding what those real stages look like, and what symptoms tend to cluster in each, is far more useful than memorizing a seven-part list that no physician would recognize.
The Real Staging System Behind Reproductive Aging
The Stages of Reproductive Aging Workshop, updated in 2011 as STRAW+10, is the internationally accepted framework researchers and clinicians use to describe the transition from peak fertility through postmenopause. It divides a woman’s reproductive life into a series of numbered stages, running from Stage −5 (early reproductive years) through Stage +2 (late postmenopause), with the final menstrual period sitting at Stage 0. The system relies on observable menstrual cycle patterns, supported by hormone markers when available.
Perimenopause, as most doctors define it, covers Stage −2 (the early menopausal transition), Stage −1 (the late menopausal transition), and the first twelve months after the final period. That is two and a half stages at most, not seven. But many women notice subtle shifts even earlier, during Stage −3a, the late reproductive stage. This is where the popular notion of extra “stages” probably originates: health writers have taken the full STRAW+10 continuum and relabeled chunks of it as stages of perimenopause, padding the count with substages that do not represent distinct clinical phases.
When Changes Begin Before the Official Transition
The late reproductive stage, Stage −3a in the STRAW+10 system, is technically still “premenopausal,” but it is where many women first sense something shifting. Periods still come regularly, but cycle lengths may shorten slightly, from the classic 28-day rhythm down to 24 or 25 days. Fertility is declining, though not obviously. The key biological change here is a drop in anti-Müllerian hormone (AMH), a marker that reflects the pool of remaining follicles in the ovaries. Research tracking AMH levels found that this hormone begins a steep decline roughly five years before the final menstrual period, and that decline may represent a critical turning point in ovarian reserve.1PubMed Central. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition AMH is considered one of the most reliable markers of where a woman sits on the reproductive aging timeline, performing at least as well as other hormone tests in predicting menopausal status.2PubMed Central. Analysis of serum levels of anti-Mullerian hormone, inhibin B, insulin-like growth factor-I, insulin-like growth factor binding protein-3, and follicle-stimulating hormone with respect to age and menopausal status
Most women in Stage −3a are in their late thirties to early forties. They may not notice anything at all, or they may experience vague changes in energy, cycle flow, or premenstrual symptoms that are easy to attribute to stress or aging in general. This is not yet perimenopause by clinical definition, but it is the prelude, and it explains why some women feel the transition started years before their periods actually became irregular.
Early Menopausal Transition
Stage −2 is where perimenopause officially begins. The hallmark is a change in menstrual cycle regularity: a persistent difference of seven or more days in the length of consecutive cycles. “Persistent” means this variability recurs within the next ten cycles, not that every single cycle is off.3PubMed Central. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging So you might have a 26-day cycle followed by a 35-day cycle, then a few normal ones, then another stretch of variability. The pattern is inconsistency itself.
Hormones at this stage are already in flux. FSH (follicle-stimulating hormone) starts climbing but bounces around, making a single blood test unreliable as a diagnostic tool. AMH continues its decline. What you feel during this phase varies enormously from person to person, but many women begin noticing the earliest vasomotor symptoms: occasional night sweats, intermittent hot flashes that may be mild enough to dismiss. Sleep may become a bit lighter. Mood shifts can appear, though they are often subtle enough that they blend into the background noise of life.
The one-to-five years before the final menstrual period are typically when cycle variability and hormonal fluctuations become hard to ignore.4PubMed. Menstrual cycle variability and the perimenopause This stage can last anywhere from a year or two to several years. There is no way to predict in advance how long it will go on for any individual woman.
Late Menopausal Transition
Stage −1 is when things get noticeably harder for most women. The defining criterion is straightforward: you skip a period for 60 days or longer.5PubMed Central. EXECUTIVE SUMMARY of STRAW+10: Addressing the Unfinished Agenda of Staging Reproductive Aging Cycles become unpredictable in both length and flow; you might have two periods in five weeks followed by nothing for three months. Ovulation becomes infrequent, though it still occurs sporadically, which means pregnancy is unlikely but not impossible.6Menopause. Cycle and hormone changes during perimenopause: the key role of ovarian function
Hormonal swings in this stage are described in the research as “extreme.” Estradiol levels can spike dramatically one week and plummet the next. FSH sometimes hits postmenopausal levels and then drops back down, especially when estradiol surges.7PubMed Central. Management of the Perimenopause These wild fluctuations, rather than a simple steady decline in estrogen, are what drive most of the symptoms women associate with perimenopause. The abrupt spikes in gonadotropins and the seesaw of estradiol and inhibin are the biological norm for this phase, and they explain why symptoms can come and go unpredictably.8PubMed. Menstrual bleeding, hormones, and the menopausal transition
The late transition typically lasts one to three years and ends when you have your final menstrual period, though you will not know it was the final one until twelve consecutive months have passed without another.
The Symptom Landscape Across the Transition
Popular lists of perimenopause symptoms tend to treat them as a single undifferentiated pile. In reality, different symptoms tend to peak at different points in the transition, and some persist long after menopause itself.
Hot Flashes, Night Sweats, and Sleep
Vasomotor symptoms, the hot flashes and night sweats most people associate with menopause, typically intensify during the late transition and peak in the first year or two after the final period. They can last for years. Sleep disruption during perimenopause has a distinct character compared to ordinary insomnia: the main problem is waking up repeatedly during the night rather than difficulty falling asleep in the first place. Research using sleep monitoring has found that perimenopausal women experience more nighttime awakenings and more time spent awake after initially falling asleep, but their total sleep time and ability to fall asleep at bedtime are often preserved.9Menopause. Sleep disturbance associated with the menopause Night sweats are a primary driver of these awakenings, and the hormonal shifts underlying them trigger a cycle of arousal that can become self-reinforcing even after the sweats improve.10Sleep Medicine Reviews. Sleep in peri-menopausal and post-menopausal women Multiple factors can pile on, including mood changes, pain, and other sleep disorders that become more common with age.11PubMed. Insomnia and menopause: a narrative review on mechanisms and treatments
Mood, Anxiety, and Cognitive Changes
The risk of clinically significant depression roughly doubles or triples during the menopausal transition compared to the premenopausal years.12PubMed Central. Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal depression: a novel heuristic model This is not just about feeling sad because of life circumstances. The fluctuations in estrogen and progesterone disrupt signaling pathways in the brain, affecting neurotransmitters like serotonin and GABA, and can dysregulate the body’s stress response system.13PubMed. Neuroendocrine mechanisms of mood disorders during menopause transition: A narrative review and future perspectives Women who have had prior episodes of depression or who are particularly sensitive to hormonal shifts (such as those who experienced severe premenstrual mood changes) appear to be more vulnerable.
Cognitive complaints, often described as “brain fog,” are also common and have a measurable basis. Brain glucose metabolism, essentially how efficiently the brain uses its fuel, begins declining during perimenopause and continues into postmenopause, likely because estrogen receptors are widespread throughout the brain and play a role in energy regulation.14PubMed Central. Cognitive Problems in Perimenopause: A Review of Recent Evidence Many women find that their verbal memory or ability to concentrate dips during the transition. The reassuring part is that for most women, these cognitive changes stabilize in postmenopause rather than continuing to worsen.
Changes That Build Slowly
Some of the most consequential effects of the menopausal transition are not the ones you feel day to day. They accumulate quietly and have long-term health implications.
Body Composition and Metabolic Shifts
Even without a change on the bathroom scale, perimenopause tends to rearrange where fat is stored. Visceral fat, the kind packed around the abdominal organs, increases, while lean muscle mass decreases. A study measuring fat distribution across menopausal stages found the shift toward central fat was most dramatic in women who started at a normal weight, with visceral fat area climbing steadily from pre- to peri- to postmenopause.15PubMed Central. The Impact of the Menopausal Transition on Body Composition and Abdominal Fat Redistribution The declining estrogen drives this redistribution and also impairs how the body burns fat, reduces insulin sensitivity in the liver, and promotes low-grade chronic inflammation, all of which raise the risk of metabolic syndrome, type 2 diabetes, and cardiovascular events.16PubMed. Perimenopause and metabolic vulnerability: hormones, body composition and lifestyle changes
Bone Density
Bone loss accelerates during the menopausal transition. In one study of perimenopausal women, roughly 38% already had osteopenia (thinning bones) and 10% had osteoporosis, with the lumbar spine particularly affected.17PubMed Central. Evaluation of Bone Mineral Density in Perimenopausal Period Estrogen plays a central role in maintaining bone density, so its decline during this period opens a window of rapid loss that continues for several years after the final period before eventually slowing.
Genitourinary Symptoms
Vaginal dryness, discomfort during sex, and urinary symptoms like urgency or recurrent infections are collectively known as the genitourinary syndrome of menopause. Unlike hot flashes, which tend to fade over time, these symptoms are typically progressive and do not resolve on their own.18PubMed. The genitourinary syndrome of menopause They result from the thinning and drying of vaginal and urinary tract tissues as estrogen levels drop, along with changes to the vaginal microbiome and local immune responses.19Menopause. The effect of pathophysiological changes in the vaginal milieu on the signs and symptoms of genitourinary syndrome of menopause (GSM) While these changes can begin during perimenopause, they often worsen after menopause, meaning many women do not address them until the symptoms are quite bothersome.
Vascular Health
The blood vessels themselves change across the transition. Endothelial function, the ability of blood vessel linings to dilate properly, appears to be relatively preserved during the early menopausal transition but deteriorates sharply in the late transition and into postmenopause, independent of age and standard cardiovascular risk factors.20PubMed Central. Vascular Aging across the Menopause Transition in Healthy Women The implication is that the remaining estrogen during early perimenopause still provides some vascular protection, and that protection drops off steeply once estrogen levels fall more permanently.
What Shifts the Timeline Earlier or Later
The average age of natural menopause is around 51, but that number hides enormous variation. Perimenopause typically begins several years earlier, often in the mid-forties, though for some women it starts in the late thirties. Several factors can push the timeline in one direction or the other.
Smoking is the strongest modifiable risk factor for earlier menopause. A large pooled analysis found that current smokers had roughly double the risk of reaching menopause before age 45 compared to women who never smoked.21PubMed Central. Cigarette Smoking and Risk of Early Natural Menopause The relationship shows a dose-response pattern: heavier smoking is associated with greater risk.22PubMed. Smoking, Genetic Susceptibility and Early Menopause: Unveiling Biological Mechanisms and Potential Therapy Targets Genetics also play a role. A family history of early menopause is one of the strongest predictors, as are being a twin, having early menarche, low parity, and being underweight.23PubMed. EMAS position statement: Predictors of premature and early natural menopause
When the Symptoms Are Not Actually Perimenopause
One of the most underappreciated pitfalls for women in their forties is assuming that every new symptom is perimenopause. Thyroid disorders, particularly hypothyroidism and hyperthyroidism, share a striking number of symptoms with the menopausal transition: fatigue, mood changes, sleep disturbance, weight shifts, menstrual irregularity, heat intolerance, and brain fog. The overlap is so extensive that researchers have flagged it as a genuine clinical problem, noting that thyroid dysfunction becomes harder to spot in this age group precisely because the symptoms blend together.24PubMed Central. Thyroid Dysfunction in Peri- and Postmenopausal Women – Cumulative Risks Studies comparing the two conditions found that thyroid-related symptoms can appear in younger women before menopause even begins, further complicating the picture.25PubMed. Comparison of the symptoms of menopause and symptoms of thyroid disease in Japanese women aged 35-59 years
The practical takeaway is that a simple TSH blood test can rule out or identify thyroid dysfunction, and experts recommend keeping a broad threshold for ordering it in perimenopausal women rather than attributing everything to hormonal change.26PubMed Central. Thyroid Dysfunction: An Alternate Plausibility in Perimenopausal Women Anemia, diabetes, and mood disorders also deserve consideration, especially if symptoms do not follow the typical perimenopausal pattern or are unusually severe.
Why Treatment Timing Matters
For women considering hormone therapy, the timing of when it starts relative to menopause appears to matter more than most people realize. The “timing hypothesis” holds that the benefits and risks of hormone replacement therapy depend heavily on how close to menopause it is initiated.27PubMed. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future Animal studies were the first to show this clearly: estrogen therapy slowed artery disease when given soon after menopause but had no benefit when delayed until plaques were already advanced.28PubMed Central. Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It’s About Time and Timing This has practical implications for anyone navigating the transition: if hormone therapy is appropriate for you, starting it during perimenopause or early postmenopause, rather than waiting years, may offer a different risk-benefit profile than starting it in your sixties.
Beyond hormone therapy, cognitive behavioral therapy has emerged as an evidence-based option specifically for menopausal symptoms. Brief programs of four to six sessions focused on vasomotor symptoms have been shown to reduce the impact of hot flashes, improve sleep, and boost quality of life.29PubMed. Cognitive behavioral therapy for menopausal symptoms This is worth knowing because many women either cannot or prefer not to use hormonal treatments, and having a non-pharmacological option with real evidence behind it broadens the toolkit considerably.
The Microbiome Connection
An emerging area of research links declining estrogen during perimenopause to shifts in the vaginal and gut microbiomes. These are not separate from the symptoms described above; they appear to be part of the mechanism behind some of them. The drop in estrogen changes the environment of the vaginal tract, reducing the population of protective lactobacilli and contributing to the dryness, irritation, and infection susceptibility that characterize genitourinary syndrome.30PubMed Central. The Genitourinary Syndrome of Menopause: An Overview of the Recent Data Less intuitively, estrogen decline also alters the gut microbiome, contributing to a state of dysbiosis that may influence the onset and progression of several age-related diseases.31Ageing Research Reviews. Aging in women – The microbiome perspective This research is still early-stage, but it represents a potential connection between the hormonal changes of perimenopause and broader patterns of aging in women, and it is generating interest in whether microbiome-targeted interventions might eventually complement existing treatments.
Why Menopause Exists at All
One of the more fascinating questions surrounding reproductive aging is why human females stop being fertile decades before the end of their natural lifespan. Most other mammals remain fertile until near death. The two leading evolutionary explanations are the “mother hypothesis,” which proposes that ceasing reproduction protects dependent children by keeping their mother alive rather than risking death in a late pregnancy, and the “grandmother hypothesis,” which suggests that post-reproductive women boost their genetic legacy by helping raise grandchildren. Research testing these hypotheses in historical populations found meaningful support for the grandmother model, pointing to the distinctive, possibly unique, role of menopause in human evolution.32PubMed Central. Testing evolutionary theories of menopause Understanding this evolutionary context does not change how perimenopause is managed, but it reframes the transition as something deeply embedded in human biology rather than a simple breakdown, and it helps explain why the process follows such a drawn-out, hormonally turbulent course rather than shutting down cleanly overnight.